Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study

Mario Cottone, Mario Cottone, Livia Biancone, Carmelina Petruzziello, Erika Angelucci, Filippo Mocciaro, Gabriele Riegler, Elisabetta Colombo, Kohn, Sostegni, Benazzato, Gianmichele Meucci, Fernando Rizzello, Claudio Papi, Fabiana Castiglione, Ambrogio Orlando, Francesco Pallone, Emma Calabrese, Geremia

Risultato della ricerca: Article

122 Citazioni (Scopus)

Abstract

Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95% confidence interval 0.46-3.84); p = 0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p = 0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40-70 years) v 45 (27-72); p = 0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.
Lingua originaleEnglish
pagine (da-a)228-233
Numero di pagine6
RivistaGut
Volume55
Stato di pubblicazionePublished - 2006

Fingerprint

Crohn Disease
Neoplasms
Infliximab
Skin Neoplasms
Breast Neoplasms
Laryngeal Neoplasms
Cholangiocarcinoma
Immunosuppressive Agents
Rectum
Non-Hodgkin's Lymphoma
Leukemia
Adenocarcinoma
Tumor Necrosis Factor-alpha

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cita questo

Cottone, M., Cottone, M., Biancone, L., Petruzziello, C., Angelucci, E., Mocciaro, F., ... Geremia (2006). Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study. Gut, 55, 228-233.

Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study. / Cottone, Mario; Cottone, Mario; Biancone, Livia; Petruzziello, Carmelina; Angelucci, Erika; Mocciaro, Filippo; Riegler, Gabriele; Colombo, Elisabetta; Kohn; Sostegni; Benazzato; Meucci, Gianmichele; Rizzello, Fernando; Papi, Claudio; Castiglione, Fabiana; Orlando, Ambrogio; Pallone, Francesco; Calabrese, Emma; Geremia.

In: Gut, Vol. 55, 2006, pag. 228-233.

Risultato della ricerca: Article

Cottone, M, Cottone, M, Biancone, L, Petruzziello, C, Angelucci, E, Mocciaro, F, Riegler, G, Colombo, E, Kohn, Sostegni, Benazzato, Meucci, G, Rizzello, F, Papi, C, Castiglione, F, Orlando, A, Pallone, F, Calabrese, E & Geremia 2006, 'Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study', Gut, vol. 55, pagg. 228-233.
Cottone M, Cottone M, Biancone L, Petruzziello C, Angelucci E, Mocciaro F e altri. Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study. Gut. 2006;55:228-233.
Cottone, Mario ; Cottone, Mario ; Biancone, Livia ; Petruzziello, Carmelina ; Angelucci, Erika ; Mocciaro, Filippo ; Riegler, Gabriele ; Colombo, Elisabetta ; Kohn ; Sostegni ; Benazzato ; Meucci, Gianmichele ; Rizzello, Fernando ; Papi, Claudio ; Castiglione, Fabiana ; Orlando, Ambrogio ; Pallone, Francesco ; Calabrese, Emma ; Geremia. / Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study. In: Gut. 2006 ; Vol. 55. pagg. 228-233.
@article{01255ebf8ec641f6a3d9b053bf799b65,
title = "Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study",
abstract = "Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22{\%}) while among the 404 CD-C, seven patients developed neoplasia (1.73{\%}) (odds ratio 1.33 (95{\%} confidence interval 0.46-3.84); p = 0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p = 0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73{\%}) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40-70 years) v 45 (27-72); p = 0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.",
author = "Mario Cottone and Mario Cottone and Livia Biancone and Carmelina Petruzziello and Erika Angelucci and Filippo Mocciaro and Gabriele Riegler and Elisabetta Colombo and Kohn and Sostegni and Benazzato and Gianmichele Meucci and Fernando Rizzello and Claudio Papi and Fabiana Castiglione and Ambrogio Orlando and Francesco Pallone and Emma Calabrese and Geremia",
year = "2006",
language = "English",
volume = "55",
pages = "228--233",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Infliximab and newly diagnosed neoplasia in CD:a multicenter matched pair study

AU - Cottone, Mario

AU - Cottone, Mario

AU - Biancone, Livia

AU - Petruzziello, Carmelina

AU - Angelucci, Erika

AU - Mocciaro, Filippo

AU - Riegler, Gabriele

AU - Colombo, Elisabetta

AU - Kohn, null

AU - Sostegni, null

AU - Benazzato, null

AU - Meucci, Gianmichele

AU - Rizzello, Fernando

AU - Papi, Claudio

AU - Castiglione, Fabiana

AU - Orlando, Ambrogio

AU - Pallone, Francesco

AU - Calabrese, Emma

AU - Geremia, null

PY - 2006

Y1 - 2006

N2 - Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95% confidence interval 0.46-3.84); p = 0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p = 0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40-70 years) v 45 (27-72); p = 0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.

AB - Background and aims: The widespread use of anti-tumour necrosis factor α antibody (Infliximab) in Crohn's disease (CD) raises concerns about a possible cancer risk in the long term. In a matched pair study, we assessed whether Infliximab is associated with an increased risk of neoplasia. Methods: In a multicentre matched pair study, 404 CD patients treated with Infliximab (CD-IFX) were matched with 404 CD patients who had never received Infliximab (CD-C). Cases and controls were matched for sex, age (±5 years), site of CD, age at diagnosis (±5 years), immunosuppressant use, and follow up. New diagnoses of neoplasia from April 1999 to October 2004 were recorded. Results: Among the 404 CD-IFX, neoplasia was diagnosed in nine patients (2.22%) while among the 404 CD-C, seven patients developed neoplasia (1.73%) (odds ratio 1.33 (95% confidence interval 0.46-3.84); p = 0.40). The survival curve adjusted for patient year of follow up showed no differences between CD-IFX and CD-C (p = 0.90; log rank test). In the CD-IFX group, there was one cholangiocarcinoma, three breast cancers, one skin cancer, one leukaemia, one laryngeal cancer, and two anal carcinomas. Among the 7/404 (1.73%) CD-C, there were three intestinal adenocarcinomas (two caecum, one rectum), one basalioma, one spinalioma, one non-Hodgkin's lymphoma, and one breast cancer. Age at diagnosis of neoplasia did not differ between groups (CD-IFX v CD-C: median 50 (range 40-70 years) v 45 (27-72); p = 0.50). Conclusion: In our multicentre matched pair study, the frequency of a new diagnosis of neoplasia in CD patients treated with Infliximab was comparable with CD patients who had never received Infliximab.

UR - http://hdl.handle.net/10447/30413

M3 - Article

VL - 55

SP - 228

EP - 233

JO - Gut

JF - Gut

SN - 0017-5749

ER -